When is evidence of lack of harm enough? Has the rosiglitazone controversy ended? Anthony L. McCall Clinical Trials Report 29 September 2009 Pages: 325 - 328
Using meal replacements as a nutritional strategy for weight loss in type 2 diabetes Amy D. Otto Clinical Trials Report 29 September 2009 Pages: 329 - 330
A new use for an old drug provides dual glucose and LDL-lowering therapy in the modern setting of T2D Management: Colesevelam HCL Ronald B. Goldberg Current Reports / Diabetes / Invited Commentary 29 September 2009 Pages: 331 - 332
What is the best treatment for prediabetes? Morali D. SharmaAlan J. Garber OriginalPaper 29 September 2009 Pages: 335 - 341
Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing? Edoardo MannucciMatteo Monami OriginalPaper 29 September 2009 Pages: 342 - 347
Treating diabetes and prediabetes by focusing on obesity management Lalita KhaodhiarSue CummingsCaroline M. Apovian OriginalPaper 29 September 2009 Pages: 348 - 354
What are the best options for controlling prandial glycemia? Stephen Clement OriginalPaper 29 September 2009 Pages: 355 - 359
What are the risks and the benefits of current and emerging weight-loss medications? Jamie R. RobinsonKevin D. Niswender OriginalPaper 29 September 2009 Pages: 368 - 375
Use of the glycemic index for weight loss and glycemic control: A review of recent evidence Sonia Vega-LópezSandra N. Mayol-Kreiser ReviewPaper 29 September 2009 Pages: 379 - 388
The usefulness of a Mediterranean-based diet in individuals with type 2 diabetes Catherine M. Champagne OriginalPaper 29 September 2009 Pages: 389 - 395
Low-carbohydrate diets: An update on current research Judith Wylie-RosettNichola J. Davis OriginalPaper 29 September 2009 Pages: 396 - 404
Fiber facts: Benefits and recommendations for individuals with type 2 diabetes Vladimir VuksanAlexander L. RogovikAlexandra L. Jenkins OriginalPaper 29 September 2009 Pages: 405 - 411